- Home
- ARVN vs CMRE Comparison
ARVN vs CMRE Comparison
Compare ARVN & CMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- CMRE
- Stock Information
- Founded
- ARVN 2015
- CMRE 1974
- Country
- ARVN United States
- CMRE Monaco
- Employees
- ARVN N/A
- CMRE N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- CMRE Marine Transportation
- Sector
- ARVN Health Care
- CMRE Consumer Discretionary
- Exchange
- ARVN Nasdaq
- CMRE Nasdaq
- Market Cap
- ARVN 1.8B
- CMRE 1.9B
- IPO Year
- ARVN 2018
- CMRE 2010
- Fundamental
- Price
- ARVN $18.48
- CMRE $12.40
- Analyst Decision
- ARVN Strong Buy
- CMRE Hold
- Analyst Count
- ARVN 13
- CMRE 2
- Target Price
- ARVN $63.00
- CMRE $13.50
- AVG Volume (30 Days)
- ARVN 967.8K
- CMRE 282.7K
- Earning Date
- ARVN 10-30-2024
- CMRE 02-05-2025
- Dividend Yield
- ARVN N/A
- CMRE 3.71%
- EPS Growth
- ARVN N/A
- CMRE N/A
- EPS
- ARVN N/A
- CMRE 3.01
- Revenue
- ARVN $161,100,000.00
- CMRE $2,030,338,000.00
- Revenue This Year
- ARVN $237.44
- CMRE $19.29
- Revenue Next Year
- ARVN N/A
- CMRE N/A
- P/E Ratio
- ARVN N/A
- CMRE $4.12
- Revenue Growth
- ARVN 1.07
- CMRE 58.37
- 52 Week Low
- ARVN $17.37
- CMRE $10.14
- 52 Week High
- ARVN $53.08
- CMRE $17.58
- Technical
- Relative Strength Index (RSI)
- ARVN 32.78
- CMRE 29.09
- Support Level
- ARVN $17.37
- CMRE $12.38
- Resistance Level
- ARVN $19.21
- CMRE $12.87
- Average True Range (ATR)
- ARVN 1.64
- CMRE 0.32
- MACD
- ARVN -0.59
- CMRE -0.06
- Stochastic Oscillator
- ARVN 11.80
- CMRE 7.38
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About CMRE Costamare Inc. $0.0001 par value
Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and among others. Costamare provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.